QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.
Metrics to compare | 317690 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship317690PeersSector | |
---|---|---|---|---|
P/E Ratio | −4.1x | −4.9x | −0.5x | |
PEG Ratio | 0.15 | −0.09 | 0.00 | |
Price/Book | 7.7x | 1.9x | 2.6x | |
Price / LTM Sales | 30.1x | 5.0x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 45.7% | |
Fair Value Upside | Unlock | 23.0% | 8.6% | Unlock |